Exon 21 L858R NSCLC Mutated Patients Treated Through Up to Six Cycles Reached 8.9-Month Median PFS; Durable Responses Beyond Two Years; and a Consistently Clean Safety Profile. "Our LP-300 program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results